Metformin use in patients with type 2 diabetes
Research type
Research Study
Full title
Metformin use in patients with type 2 diabetes
IRAS ID
259495
Contact name
James C McElnay
Contact email
Sponsor organisation
Queen's University Belfast
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Not taking medicine as prescribed by the doctor (poor medication adherence) remains an important issue in diabetes patients and is a key factor for failure to achieve treatment goals. It is associated with poor disease control, increased incidence of hospital admissions, long-term complications, increased mortality rates and increased healthcare costs. Metformin is a first-line medication for type 2 diabetes in the UK and has been found to have the lowest adherence rates when compared with other similar medicines for diabetes.
The principal aim of this study is to evaluate the management of metformin treatment, in particular medication adherence, in patients with type 2 diabetes attending outpatient clinics in the South Eastern Health & Social Care Trust (SEHSCT) in Northern Ireland. This will be evaluated using different adherence assessment measurements, including: self-reported questionnaires, pharmacy records, general practitioner prescribing records and using low volume blood samples taken from a finger prick. The secondary aim is to determine factors which are associated with non-adherence with prescribed metformin.REC name
London - Bromley Research Ethics Committee
REC reference
19/LO/0804
Date of REC Opinion
24 Jun 2019
REC opinion
Further Information Favourable Opinion